Danshen: An Overview of Its Chemistry, Pharmacology, Pharmacokinetics, and Clinical Use | 2005/12/01 | English | 987 |
A Classification of Antiarrhythmic Actions Reassessed After a Decade of New Drugs | 1984/04/01 | English | 491 |
The Anticholinergic Drug Scale as a Measure of Drug‐Related Anticholinergic Burden: Associations With Serum Anticholinergic Activity | 2006/12/01 | English | 467 |
Pharmacokinetics and Bioavailability of Quercetin Glycosides in Humans | 2001/05/01 | English | 418 |
Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual‐Acting Angiotensin Receptor—Neprilysin Inhibitor (ARNi) | 2010/04/01 | English | 380 |
A Mechanistic Approach to Understanding the Factors Affecting Drug Absorption: A Review of Fundamentals | 2002/06/01 | English | 378 |
Global Burden of Disease (GBD) for Hepatitis C | 2004/01/01 | English | 353 |
DHEA and DHEA‐S: A Review | 1999/04/01 | English | 345 |
Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers | 2010/07/01 | English | 334 |
Multiple Drug Resistance in Cancer Revisited: The Cancer Stem Cell Hypothesis | 2005/08/01 | English | 302 |
Cannabidiol: An Overview of Some Pharmacological Aspects | 2002/11/01 | English | 301 |
Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel in Humans | 2010/02/01 | English | 295 |
Stability and Performance of a Population Pharmacokinetic Model | 1997/06/01 | English | 274 |
Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Bone Metastases | 2002/11/01 | English | 273 |
New Era in Drug Interaction Evaluation: US Food and Drug Administration Update on CYP Enzymes, Transporters, and the Guidance Process | 2008/06/01 | English | 265 |
Nuclear Receptors and the Regulation of Drug‐Metabolizing Enzymes and Drug Transporters: Implications for Interindividual Variability in Response to Drugs | 2007/05/01 | English | 262 |
Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59‐7939) in Healthy Subjects | 2007/02/01 | English | 256 |
Nuclear Factor Kappa B: Important Transcription Factor and Therapeutic Target | 1998/11/01 | English | 255 |
Effects of Celecoxib, a Novel Cyclooxygenase‐2 Inhibitor, on Platelet Function in Healthy Adults: A Randomized, Controlled Trial | 2000/02/01 | English | 244 |
Pharmacokinetics and Bioavailability of Mycophenolate Mofetil in Healthy Subjects after Single‐Dose Oral and Intravenous Administration | 1996/04/01 | English | 242 |
Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's Sarcoma | 1996/01/01 | English | 237 |
Dose‐Dependent Pharmacokinetics and Psychomotor Effects of Caffeine in Humans | 1997/08/01 | English | 235 |
Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches | 2009/05/01 | English | 225 |
Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel | 2008/04/01 | English | 223 |
Effects of Nonsteroidal Antiinflammatory Drugs on Platelet Function and Systemic Hemostasis | 1995/03/01 | English | 219 |
Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement | 2005/05/01 | English | 211 |
Human Drug Metabolism and the Cytochromes P450: Application and Relevance of In Vitro Models | 2001/11/01 | English | 210 |
Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX‐2 versus COX‐1 in Healthy Volunteers | 2000/10/01 | English | 210 |
Hemodynamic Response to the Upright Posture | 1994/05/01 | English | 206 |
Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis | 2015/12/22 | English | 206 |